[Comment] Optimising treatment strategies in older patients with mantle cell lymphoma

The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with immunochemotherapy, constitutes the new standard of care following the recent approval of ibrutinib and acalabrutinib for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma, respectively.1–3 In younger and fitter patients, ibrutinib is administered in combination with R-CHOP (rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone) alternating with R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) as induction, followed by optional autologous haematopoietic stem-cell transplantation and time-limited maintenance.